IP Library Granted Patent US 10,729,744
Granted Patent B2
US 10,729,744 · App. 15/943,058 · Granted Aug 4, 2020

Reelin rescues cognitive function

Inventors: Edwin Weeber (Apollo Beach, FL); Lisa Zhao (Alhambra, CA); Melinda Peters (Riverview, FL)
Assignees: University of South Florida; Vanderbilt University
A61K38/1709A61K38/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,729,744
App. No.
15/943,058
Granted
Aug 4, 2020
Kind
B2
Abstract

Disclosed are methods of influencing, and enhancing, cognitive function and memory by increasing, and/or preventing interference with, Reelin levels as well as Reelin signaling. Cognitive function is improved, in a subject in need thereof, by administering a therapeutically effective amount of Reelin, a Reelin-specific modulator or an agonist of a lipoprotein receptor to the subject. The lipoprotein receptor can be selected from candidates such as ApoER2 and VLDLR. As disclosed herein, agonists of the lipoprotein receptor for use with the inventive method include APC, Sep and Fc-RAP. In addition to administering exogenous Reelin, a Reelin-specific modulator, such as a recombinant Reelin fragment, can be used to increase Reelin levels and/or signaling.

Claims (7)

1. A method of improving memory in a subject comprising:

administering a therapeutically effective amount of a Reelin fragment to a subject;

wherein the Reelin fragment is a 450 kDa Reelin protein fragment, a 370 kDa Reelin protein fragment, a 180 kDa Reelin protein fragment, or a combination thereof to the subject.

2. The method of claim 1 , wherein the subject suffers from a disease or disorder of the nervous system selected from the group consisting of fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, Parkinson's disease, Duchenne muscular dystrophy, Reelin deficiency, schizophrenia and stroke.

3. The method of claim 2 , wherein the disease or disorder of the nervous system is characterized by a symptom selected from the group consisting of a deficiency in dendritic spine density and diminished synaptic plasticity.

4. The method of claim 1 , wherein long term memory in the subject is improved.

5. The method of claim 1 , wherein the Reelin fragment is administered once a day or every other day.

Assignments (4)
CONFIRMATORY LICENSE Recorded May 25, 2018
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046245/0966 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2018
From: WEEBER, EDWIN
To: UNIVERSITY OF SOUTH FLORIDA; VANDERBILT UNIVERSITY
Reel/Frame 045420/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2018
From: ZHAO, LISA
To: VANDERBILT UNIVERSITY
Reel/Frame 045420/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2018
From: PETERS, MELINDA
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 045420/0621 →
Continuity (5)
Continuation 14969959 · Dec 15, 2015
Continuation 13206174 · Aug 9, 2011
Continuation PCTUS2010023615 · Feb 9, 2010
Provisional Application 61150890 · Feb 9, 2009
Related Publication 20180236028A1 · Aug 23, 2018